Christopher McNulty
2017
In 2017, Christopher McNulty earned a total compensation of $707.6K as Chief Financial Officer at InVivo Therapeutics Holdings, a 25% increase compared to previous year.
Compensation breakdown
| Option Awards | $362,290 |
|---|---|
| Salary | $328,127 |
| Other | $17,220 |
| Total | $707,637 |
McNulty received $362.3K in option awards, accounting for 51% of the total pay in 2017.
McNulty also received $328.1K in salary and $17.2K in other compensation.
Rankings
In 2017, Christopher McNulty's compensation ranked 10,566th out of 14,666 executives tracked by ExecPay. In other words, McNulty earned more than 28.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 10,566 out of 14,666 | 28th |
Division Manufacturing | 4,110 out of 5,772 | 29th |
Major group Measuring, Analyzing, And Controlling Instruments; Photographic, Medical And Optical Goods; Watches And Clocks | 553 out of 859 | 36th |
Industry group Surgical, Medical, And Dental Instruments And Supplies | 325 out of 531 | 39th |
Industry Surgical and Medical Instruments and Apparatus | 207 out of 336 | 38th |
Source: SEC filing on April 27, 2018.
McNulty's colleagues
We found six more compensation records of executives who worked with Christopher McNulty at InVivo Therapeutics Holdings in 2017.
2017
Mark Perrin
InVivo Therapeutics Holdings
Chief Executive Officer
2017
Richard Toselli
InVivo Therapeutics Holdings
Chief Executive Officer
2017
Thomas Ulich
InVivo Therapeutics Holdings
Chief Scientific Officer
2017
Tamara Joseph
InVivo Therapeutics Holdings
General Counsel
2017
Pamela Stahl
InVivo Therapeutics Holdings
Former Chief Commercial Officer
2017
Melanie Morel-Ferris
InVivo Therapeutics Holdings